U.S. Markets closed

Cardiovascular Systems, Inc. (CSII)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.12+0.79 (+1.87%)
At close: 4:00PM EDT
43.12 -0.00 (-0.00%)
After hours: 04:04PM EDT

Cardiovascular Systems, Inc.

1225 Old Highway 8 Northwest
Saint Paul, MN 55112-6416
United States
651 259 1600

IndustryMedical Devices
Full Time Employees779

Key Executives

NameTitlePayExercisedYear Born
Mr. Scott Raymond Ward M.S., MS, B.Sc.Chairman, Pres & CEO1.17MN/A1960
Mr. Jeffrey S. PointsChief Financial Officer507.49kN/A1977
Ms. Rhonda J. RobbChief Operating Officer830.22kN/A1968
Mr. Alexander RosensteinGen. Counsel & Corp. Sec.523.26kN/A1972
Dr. Ryan D. Egeland M.D., Ph.D.Chief Medical Officer490.64kN/A1975
Mr. John E. NielsenVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Sandra M. SedoChief Compliance OfficerN/AN/A1964
Mr. David S. WhitescarverVP of Corp. Devel. & Intellectual PropertyN/AN/A1958
Mr. Stephen J. RempeChief HR OfficerN/AN/A1973
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

Corporate Governance

Cardiovascular Systems, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 3. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.